

Pelacarsen Roll-over Extension Program

NCT06875973

Status	RECRUITING
Phase	Phase 3
Sponsor	Novartis Pharmaceuticals
Enrollment	599 participants

Key Eligibility Criteria

Inclusion (2)

- Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
- Participants who have completed the parent study and received the assigned study treatment at the time of its completion

Exclusion (4)

- Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study
- Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation
- Participants who are receiving another investigational drug or device before the open-label treatment period
- Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator

Locations (95 total)

Parkway Medical Center, Birmingham, Alabama, United States
Cardiology and Medicine Clinic PA, Little Rock, Arkansas, United States
National Heart Institute, Beverly Hills, California, United States
... and 92 more locations